- Home
- HASI vs CELC Comparison
HASI vs CELC Comparison
Compare HASI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HASI
- CELC
- Stock Information
- Founded
- HASI 1981
- CELC 2011
- Country
- HASI United States
- CELC United States
- Employees
- HASI N/A
- CELC N/A
- Industry
- HASI Real Estate Investment Trusts
- CELC Medical Specialities
- Sector
- HASI Real Estate
- CELC Health Care
- Exchange
- HASI Nasdaq
- CELC Nasdaq
- Market Cap
- HASI 3.4B
- CELC 3.1B
- IPO Year
- HASI 2013
- CELC 2017
- Fundamental
- Price
- HASI $33.57
- CELC $98.95
- Analyst Decision
- HASI Strong Buy
- CELC Strong Buy
- Analyst Count
- HASI 8
- CELC 7
- Target Price
- HASI $39.50
- CELC $95.29
- AVG Volume (30 Days)
- HASI 1.4M
- CELC 895.4K
- Earning Date
- HASI 11-06-2025
- CELC 11-12-2025
- Dividend Yield
- HASI 5.01%
- CELC N/A
- EPS Growth
- HASI 27.54
- CELC N/A
- EPS
- HASI 2.32
- CELC N/A
- Revenue
- HASI $99,644,000.00
- CELC N/A
- Revenue This Year
- HASI $184.74
- CELC N/A
- Revenue Next Year
- HASI N/A
- CELC N/A
- P/E Ratio
- HASI $14.49
- CELC N/A
- Revenue Growth
- HASI N/A
- CELC N/A
- 52 Week Low
- HASI $21.98
- CELC $7.58
- 52 Week High
- HASI $34.28
- CELC $103.06
- Technical
- Relative Strength Index (RSI)
- HASI 62.93
- CELC 76.82
- Support Level
- HASI $31.98
- CELC $92.10
- Resistance Level
- HASI $33.68
- CELC $96.10
- Average True Range (ATR)
- HASI 1.19
- CELC 5.41
- MACD
- HASI 0.04
- CELC 0.90
- Stochastic Oscillator
- HASI 87.10
- CELC 86.23
About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.